%PDF- %PDF-
Mini Shell

Mini Shell

Direktori : /var/www/html/diaspora/api/public/imperial-topaz-htulmbl/cache/
Upload File :
Create Path :
Current File : /var/www/html/diaspora/api/public/imperial-topaz-htulmbl/cache/c83685d6a97987c3c97a1e85b536233b

a:5:{s:8:"template";s:13490:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="IE=edge" http-equiv="X-UA-Compatible"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="https://fonts.googleapis.com/css?family=Lato%3A100%2C300%2C400%2C700%2C900%2C100italic%2C300italic%2C400italic%2C700italic%2C900italic&amp;ver=4.9.13" id="redux-google-fonts-rdx_option-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">@charset "UTF-8";.site-content:after,.site-content:before{content:"";display:table}.site-content:after{clear:both}html{overflow-y:scroll}body{color:#575756;background-repeat:no-repeat;background-attachment:fixed;background-position:center;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;margin-top:-1px;overflow-x:hidden}h2{font-weight:400}h2{font-size:30px;line-height:44px}a{color:#428bff;cursor:pointer}a:focus{outline:0}p{margin-bottom:25px}@media (max-width:1200px){body{font-size:14px!important;line-height:24.5px!important}p{margin-bottom:21.875px;font-size:14px}}.navbar{border:none;border-bottom:1px solid transparent}.widget{margin-bottom:40px}.widget:first-of-type h2{margin-top:0}.widget h2{font-size:16px;color:#2b4269;font-weight:700;margin-bottom:10px}.li-footer h2{margin-top:0;color:#428bff}.li-footer p{margin-bottom:15px}.li-footer .footer-widget-bar .container{padding-top:85px;padding-bottom:70px}.li-footer .footer-copyright .container{padding-top:26px;padding-bottom:26px}.li-footer-style-1 .footer-widget-bar{background-color:#f8f9fc}.li-footer-style-1 .footer-copyright{background-color:#2b4269;color:#fff}@media (max-width:768px){.li-footer .footer-copyright{text-align:center}}.li-header{background-color:#fff;box-shadow:0 1px 3px 0 rgba(0,0,0,.15);transition:background-color .5s ease}.li-header .navbar{margin-bottom:0}.li-header.header-style-1 .navbar{min-height:80px}.li-header.header-style-1 .mega_main_menu .menu_holder .menu_inner>ul>li{padding-bottom:20px}.li-header.header-style-1 .mega_main_menu .menu_holder{padding:20px 0 0 0}.mega_main_menu .menu_holder{padding:20px 0 0 0}@media (max-width:959px){.mega_main_menu .menu_holder{padding-bottom:20px}.mega_main_menu>.menu_holder>.menu_inner>ul{background-color:rgba(0,0,0,.5)}.mega_main_menu .menu_holder .menu_inner>ul>li{padding:5px!important;border-bottom:1px solid rgba(255,255,255,.3)!important}} html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background-color:transparent}a:active,a:hover{outline:0} *{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}h2{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}h2{margin-top:20px;margin-bottom:10px}h2{font-size:30px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.row{margin-right:-15px;margin-left:-15px}.col-md-4,.col-sm-8{position:relative;min-height:1px;padding-right:15px;padding-left:15px}@media (min-width:768px){.col-sm-8{float:left}.col-sm-8{width:66.66666667%}}@media (min-width:992px){.col-md-4{float:left}.col-md-4{width:33.33333333%}}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}.container:after,.container:before,.navbar:after,.navbar:before,.row:after,.row:before{display:table;content:" "}.container:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width} style{display:none!important;max-width:0!important;max-height:0!important;visibility:hidden!important;opacity:0!important}.mega_main_menu ul:after,.mega_main_menu:after,.mega_main_menu:before{content:'';display:table;clear:both;float:none;width:100%;height:0;border:0 none}.mega_main_menu{float:none;position:relative;margin:0;height:inherit;-webkit-transition:all .4s;-moz-transition:all .4s;-ms-transition:all .4s;-o-transition:all .4s;transition:all .4s}.mega_main_menu *{-webkit-box-sizing:border-box!important;-moz-box-sizing:border-box!important;-ms-box-sizing:border-box!important;-o-box-sizing:border-box!important;box-sizing:border-box!important;outline:0}.mega_main_menu .item_link *{line-height:131%}.mega_main_menu a{cursor:default}.mega_main_menu a[href]{cursor:pointer}.mega_main_menu ul.mega_main_menu_ul{position:relative;margin:0;padding:0}.mega_main_menu,.mega_main_menu>.menu_holder,.mega_main_menu>.menu_holder>.menu_inner,.mega_main_menu>.menu_holder>.menu_inner>.mega_main_menu_ul{font-size:0;letter-spacing:0;word-spacing:0;line-height:0;display:block;visibility:visible;overflow:visible;-webkit-backface-visibility:hidden}.mega_main_menu>.menu_holder{position:relative}.mega_main_menu>.menu_holder>.mmm_fullwidth_container{position:absolute;top:0;bottom:0;left:0;right:0;height:100%;width:100%}.mega_main_menu>.menu_holder>.menu_inner>ul{z-index:2000;list-style:none;float:none;width:auto;position:relative;top:auto;bottom:auto;left:auto;right:auto;border:0 none;background:0 0}.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link *{font-size:inherit;letter-spacing:normal;word-spacing:normal;line-height:inherit}.mega_main_menu .nav_logo{display:block;vertical-align:top;float:left;position:relative;z-index:2100}.mega_main_menu>.menu_holder>.menu_inner>ul>li{display:inline-block;vertical-align:top;margin:0;padding:0;float:none;height:auto;width:auto;overflow:visible;background-color:transparent;border:0 none}.mega_main_menu>.menu_holder>.menu_inner>ul>li[class*=columns]{width:auto}.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link{text-shadow:none;text-transform:none;position:relative;display:block;padding:0 17px;margin:0;top:auto;bottom:auto;left:auto;right:auto}.mega_main_menu>.menu_holder>.menu_inner>ul>li .item_link{width:auto;height:auto;min-width:inherit;max-width:inherit}.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link>.link_content{display:block;float:none;padding:0;position:static;border:0 none}.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link .link_text{white-space:normal;word-wrap:break-word;word-break:normal;display:table-cell;line-height:120%;vertical-align:middle;position:static;padding:0;border:0 none;height:auto}.mega_main_menu a.disable_icon>i,.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link.disable_icon i{display:none}.mega_main_menu ul>li a.item_link{text-decoration:none}.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link:after{content:'';display:block;width:0;height:0;position:absolute;top:50%;right:5px;margin-top:-2px;border-width:4px 3px;border-style:solid}.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link:last-child:after{display:none}.mega_main_menu>.menu_holder>.menu_inner>ul li>.item_link:hover{box-shadow:none;float:none;text-decoration:none}.mega_main_menu>.menu_holder>.menu_inner>ul li>a.item_link:hover{cursor:pointer}.mega_main_menu .item_link>.link_content>.link_text{display:inline;white-space:normal;word-wrap:break-word;word-break:normal}.mega_main_menu li.menu-item{position:relative}@media (max-width:1199px){.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link{padding-left:13px;padding-right:13px}}@media (max-width:991px){.mega_main_menu>.menu_holder>.menu_inner>ul>li>.item_link{padding-left:10px;padding-right:10px}}@media (max-width:959px){.mega_main_menu>.menu_holder>.menu_inner>ul li,.mega_main_menu>.menu_holder>.menu_inner>ul li>.item_link{cursor:pointer}.mega_main_menu.responsive-enable>.menu_holder>.menu_inner{width:auto!important}.mega_main_menu.responsive-enable>.menu_holder>.menu_inner>.nav_logo{float:none}.mega_main_menu.responsive-enable>.menu_holder>.menu_inner>.nav_logo:after{content:'';display:table;clear:both;width:100%;height:0;position:relative}.mega_main_menu.responsive-enable>.menu_holder>.menu_inner>ul>li>.item_link:before{display:none}.mega_main_menu.responsive-enable>.menu_holder>.menu_inner>ul>li{float:none;display:block;width:100%}.mega_main_menu.responsive-enable li>.item_link{float:none}.mega_main_menu.responsive-enable>.menu_holder>.menu_inner>ul>li>.item_link:after{right:5px;left:auto;border-width:4px 3px;border-top-color:inherit;border-right-color:transparent!important;border-bottom-color:transparent!important;border-left-color:transparent!important}}.mega_main_menu.primary{min-height:40px}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link>.link_content{height:40px;line-height:40px}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link>.link_content>.link_text{height:40px}@media (max-width:959px){.mega_main_menu.primary{min-height:40px}}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link>i{width:35px}.mega_main_menu.primary>.menu_holder>.mmm_fullwidth_container{background-color:#253c58}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link .link_text{font-family:inherit;font-size:16px;font-weight:400;text-transform:none}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link>i{font-size:20px}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link>i:before{width:20px}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link *{color:#fff}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link:after{border-color:#fff;color:#fff}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link{background-color:#253c58}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li:hover>.item_link,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link:focus,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link:hover{background-color:#253c58}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li:hover>.item_link,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li:hover>.item_link *,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link:focus,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link:hover,.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li>.item_link:hover *{color:#f8f8f8;border-color:#f8f8f8}.mega_main_menu.primary>.menu_holder>.menu_inner>ul>li:hover>.item_link:after{border-color:#f8f8f8}.mega_main_menu.primary>.menu_holder>.mmm_fullwidth_container{border-radius:0}.mega_main_menu.primary>.menu_holder>.menu_inner>span.nav_logo{border-radius:0}.mega_main_menu .menu_holder .menu_inner>ul>li{padding-bottom:20px}</style>
 </head>
<body class="">
<div class="page-container fluid" id="li-page-top">

<div class="li-header header-style-1 show">

<nav class="navbar">

<div class="mega_main_menu primary primary_style-flat responsive-enable" id="primary">
<div class="menu_holder">
<div class="mmm_fullwidth_container"></div>
<div class="menu_inner" role="navigation">
<span class="nav_logo">
<h2 style="color:white;">
{{ keyword }}
</h2>
</span>
<ul aria-label="MENU" class="mega_main_menu_ul" id="main_ul-primary" role="menubar">
<li class="scroll-to menu-item menu-item-type-custom menu-item-object-custom menu-item-13 default_dropdown default_style drop_to_right submenu_default_width columns1" id="menu-item-13">
<a class="item_link disable_icon" href="#" role="menuitem" tabindex="0">
<i class=""></i>
<span class="link_content">
<span class="link_text">
				Home
			</span>
</span>
</a>
</li>
<li class="scroll-to menu-item menu-item-type-custom menu-item-object-custom menu-item-50 default_dropdown default_style drop_to_right submenu_default_width columns1" id="menu-item-50">
<a class="item_link disable_icon" href="#" role="menuitem" tabindex="0">
<i class=""></i>
<span class="link_content">
<span class="link_text">
				Services
			</span>
</span>
</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-56 default_dropdown default_style drop_to_right submenu_default_width columns1" id="menu-item-56">
<a class="item_link disable_icon" href="#" role="menuitem" tabindex="0">
<i class=""></i>
<span class="link_content">
<span class="link_text">
				Blog
			</span>
</span>
</a>
</li>
</ul>
</div>
</div>
</div>
</nav>
</div>

<div class="hfeed site -topbar" id="page">
<div class="site-content" id="content">
{{ text }}
</div>
<footer class="li-footer li-footer-style-1" id="colophon">
<div class="footer-widget-bar footer-row">
<div class="container">
<div class="row">
<div class="col-md-4">
<div class="footer-widget">
<div class="widget widget_text"><h2>Related</h2> <div class="textwidget">
{{ links }}
<p> </p>
</div>
</div> </div>
</div>
</div>
</div>
</div>
<div class="footer-copyright footer-row">
<div class="container">
<div class="row">
<div class="col-sm-8">
<div class="site-info">
{{ keyword }} 2021</div>
</div>
</div>
</div>
</div>
</footer>
</div>
</div>
</body>
</html>";s:4:"text";s:30352:"Sana is building a fully-integrated cell therapy company. Please. The company's cells can create a new class of medicines to treat a broad array of diseases, enabling patients to have access to new and meaningful medicines. Seattle-based Sana Biotechnology is shooting to raise $150 million in its initial public offering, but soon after is expected to see its market value to soar to more than $10 billion, according to leading industry publication BioSpace. Sana Biotechnology is set to start trading on Thursday. Analyze detailed company data and 20 years of filings. There are two types of MHC molecules: MHC class I, expressed on the surface of almost all nucleated cells, and MHC class II, expressed constitutively on professional antigen presenting cells (APC), including macrophages and dendritic cells . Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. S-1MEF - Sana Biotechnology, Inc. (0001770121) (Filer) Source: SEC S-1 Filings Published on 2021-02-03 S-1MEF - Sensei Biotherapeutics, Inc. (0001829802) (Filer) Sana’s two most advanced drug candidates are hypoimmune CAR-T cell therapies, SC291 and SC255 - SC291 targets CD19 for NHL, CLL, and ALL and SC255 targets BCMA for multiple myeloma. Your access to, and use of, our website is subject to our Terms of Use ​and all applicable laws and regulations. It stood for "F--- Disease." As no active threats were reported recently by users, sanabiotechnology.com is SAFE to browse. T1DM affects around 1.6M people in the US and 2.4M in Europe. KIRs recognize self MHC class I molecules on the surface of cells and provide inhibitory signals to the NK cells to prevent their activation. Cells missing MHC class I molecules are corresponding eliminated by NK cells because of the lack of inhibitory KIR signaling and a resulting cytolytic activation.”, Sana’s hypoimmune cells are working to avoid both the adaptive and innate immune response. T cells belong to the adaptive immune system, recognizing and eliminating non-self cells via recognition of differences in cell-surface proteins encoded by the major histocompatibility (MHC) locus. He is a professor emeritus at Harvard Medical School. Without any clinical assets, the company’s value is really in its future ability to develop cell therapies that can be manufactured more easily and for more diseases than incumbents: “Delivery - we believe the critical limitation for in vivo cell engineering is delivery, and therefore, we are investing significantly in delivery technologies, including our fusogen technology, which is designed to enable both cell-specific delivery and delivery of diverse payloads”, “Gene modification - there has been substantial recent progress in gene modification and the field is now at the point where virtually any desired modification can be performed in vitro. Sana’s initial focus is on T-cells, hepatocytes, and hematopoietic stem cells (HSCs); however, their technology could expand to glia cells and beta islets. Sana Biotechnology Inc., co-founded in 2018 by Cambridge VC firm Flagship Pioneering, F-Prime Capital, Arch Venture Partners and former Juno executives Hans Bishop and … We invest in early-stage life sciences companies often when they are no more than an idea. As a team with expertise ranging from cellular biology to machine learning to development of therapeutics, all of us are dedicated to developing cures for patients. We are excited to be in business with you - email us at   info@axialvc.com. UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor December 16, 2020 UNITY Biotechnology Reports Granting of New Employment Inducement Awards Sana Biotechnology is a cell therapy company, recently filing an S-1, founded in 2018 to build a platform for in vivo and ex vivo cell engineering. We use cookies to improve your experience on our website. To find out more, read our, This site requires JavaScript to run correctly. Alternatively, you can communicate with the author(s) of the (upcoming) … The Company focuses on creating and delivering engineered cells as medicine for patients. 7646 Food and Animal Biotechnology (Food Science and Biotechnology; Animal Science and Biotechnology) 7647 ... S1 or S2 yang mana paling bagus dan berapa tempoh pengajiannya? The humoral immune response leads to antibody production against foreign proteins, In allogeneic transplants, the cellular and humoral processes can recognize proteins from the donor as ‘foreign’, resulting in an immune response to the transplant including potential elimination of the transplanted cells. To learn more about how we use cookies, please see our Privacy Policy. However, no single technology or platform is optimal for all possible applications.To this end, we are developing capabilities across multiple technologies and investing to develop our own novel technologies to be applied on a case-by-case basis.”, “Manufacturing - we are investing proactively in process development, analytical development, CMC regulatory, and other manufacturing sciences in order to enable scalable manufacturing of our in vivo therapies and ensure broad access”. The era of engineering cells can deliver unprecedented benefits. Sana Biotechnology, Inc. operates as a biotechnology company. To enable cell therapy on a broader scale, the development of universal donor stem cell products that can be administered to multiple patients in need has been proposed, yet a strategy controlling both adaptive and innate immune rejection has not been reported. “Natural killer (NK) cells express receptors known as inhibitory killer-cell immunoglobulin-like receptors (inhibitory KIRs). Sana’s current valuation is mainly in its platform. Sana Biotechnology, Former Juno Therapeutics Execs Co-Found New Biotech. All rights reserved. Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. When it launched, the buzzy startup Sana Biotechnology went by a pluckier code name: FD Therapeutics. William Bernal consults for Sana Biotechnology. On January 4, 2019, Sana Biotechnology became the latest regenerative medicine company to enter the marketplace, founded by former Juno Therapeutics executives Hans Bishop and Steve Harr, among other all-star executives. The company was built to bring these technologies to cancer but diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders as well. More on this story. Christian Hordo is the Chief Business  of Sana where he previously was a VP Juno and a team leader at Genentech. Here are 5 crucial takeaways from Sana's 271-page filing. Tambahkan komentar. All rights reserved. While he was a professor, Mulligan advised Icahn Capital in biotechnology investments and was a founding partner at Sarissa Capital Management. Sunil Agarwal is also a Co-Founder of Sana and is the Chief Medical Officer. However, immune rejection has been a barrier to bring this tool to more diseases: “Studies established T cells as playing a key role in the host immune response to transplant. Balas Hapus. The core technology for Sana is around the company’s ability to generate hypoimmune cells: “Disruption of MHC class I and class II expression (which inactivates adaptive immune responses), and overexpression of CD47 (which hides cells from the innate immune system, including macrophages and natural killer (NK) cells)”, “Pluripotent stem cells from healthy donors are used as the starting material and are then genetically modified with the hypoimmune edits”, “These edited cells are then differentiated into cell types of therapeutic interest, which are administered to the patient as ‘off the shelf’ therapies”. InBrief BRIEF—Neurogene raises $68.5 million in series A round. 2A, Part 77.This act, also known as the Truth in Securites Act was inacted to bring greater transparency to securities. However, if a cell displays a peptide from a foreign or mutated protein on MHC class I, for example as a result of a protein mutation, it may result in the activation of a cytotoxic T cell response specific to the peptide-MHC complex via the T cell receptor (TCR) on the T cell surface. For the CNS disorders Sana is addressing, multiple sclerosis affects approximately 1.6M people  and Huntington’s disease affects approximately 90,000 people in the US. Richard Mulligan heads SanaX, the R&D division of Sana. Sana’s initial focus is on T-cells (CD8+ and CD4+) targeting CD19 in oncology from NHL to CLL and ALL. The company was built to bring these technologies to cancer but diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders as well. Cells display peptides from normal self proteins on MHC class I, which typically will not activate an immune response due to a process called tolerance, where the body recognizes these peptides as self . These emerging capabilities will create novel medicines that meaningfully improve patient outcomes, and Sana aims to lead the way. Expression of MHC class II is also induced in many additional cells in the context of inflammation. Sana Biotechnology launches, with focus on engineering cell and gene therapies 08-01-2019 Print. ... bismillah planning beasiswa full di sana. Adaptive Biotechnologies is an Equal Opportunity Employer. In the allogeneic setting, MHC proteins can be highly immunogenic due to their inherent polymorphism, increasing the risk of the recognition of transplants as foreign. 258. ⓒ 2020-2021 Sana Biotechnology. from the patient’s own cells) to avoid host rejection. The company is also developing stem cell-derived allogeneic glial progenitor cells (GPC) that can differentiate into myelin-producing oligodendrocytes or astrocytic support cells for neurons to treat MS, Huntington’s disease, and myelin diseases. 1 users have flagged Sana Biotechnology as a Scam with an aggregate rating of 1. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. At Sana, we understand that each disease is unique, and finding the best treatment requires a deep understanding of its genetic and cellular underpinnings. Virtually every human disease begins with cells. However, after birth, few if any children would qualify as a matched donor for a cell or organ transplant for their mother These scientists categorized the differences of the maternal-fetal border and systematically tested them to understand which, if any, of these were most important to immune evasionThey have tested these changes in both in vitro and in vivo animal models.”. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. Sana Biotechnology is a cell therapy company, recently filing an S-1, founded in 2018 to build a platform for in vivo and ex vivo cell engineering. This site uses cookies. 16-04-2019. Justia Trademarks Categories Pharmaceuticals SANA BIOTECHNOLOGY - Trademark Details SANA BIOTECHNOLOGY - Trademark Details Status: 731 - Second Extension - Granted Steven Harr (CEO) still owns a pretty significant amount (over 5%) given that the company raised so much capital ($700M) from day one. Esto te garantiza una experiencia conveniente y confiable para tus clientes, desarrollando la agilidad que requieres para responder rápidamente a sus necesidades. Sana’s Co-Founder, President, and CEO is Steven Harr. Sino Biological is committed to providing high-quality recombinant protein, antibody, cDNA clone and ELISA Kit reagents and to being a one-stop technical services … SEC Form S-1 is a registration filing form for companies to complete registration of securities offering under the Securities Act of 1933 [] (see also, 15 USC Ch. Sana Commerce elimina los datos aislados haciendo que tu ecommerce y tu ERP SAP o SAP Business One funcionen como uno solo. “Prioritize program investments in diseases where the strengths of our in vivo and ex vivo platforms can address key limitations of existing therapeutic approaches”, “Focus on conditions of high unmet need, including the most grievous diseases”, “Prioritize efforts where success in one area begets success in others”. Sana Biotechnology General Information Description. This website is estimated worth of $ 8.95 and have a daily income of around $ 0.15. These peptide-MHC complexes interact with TCRs on helper T cells, such as CD4+ T cells, resulting in a downstream cellular and humoral immune response. Newer Story Older Story. Click the link we sent to , or click here to log in. They use their fusogen technology to selectively deliver vehicles through specific cell surface receptors (like CD8) that create fusosomes and deliver a payload into a cell. This underlies the basis for MHC typing and matching to assess and reduce the risk of organ transplant rejection.”, Other companies have focused on downregulation or deleting MHC. Share your experience with Sana Biotechnology to help others make better choices Sana Biotechnology - 1 Reviews, Complaints & Ripoffs at HolySmoke.org ARCH and Flagship dominate the cap table since they put up a few $100M to get Sana started. avoid detection from the human immune system) cell therapies from iPSCs or an allogeneic cell particularly for T-cells. To avoid this problem, Sana is centered around technology to generate hypoimmune (i.e. Their approach has been to develop technologies in house and also acquire them, as with the fusogen IP, in a land grab strategy: “Minimize biology risk where there is platform risk, or in other words, prioritize opportunities where success with our platform should lead to success in addressing the underlying disease.” This is expressed by Sana’s focus on CD19, a derisked target in oncology, to get to clinical validation with the goal to expand to newer targets. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. By accessing and using our website, you accept these Terms of Use. For the latter, Sana brings their hypoimmune technology versus the standard to use drugs to eliminate a patient’s immune system. For your security, we need to re-authenticate you. Find the best stocks to buy. Sana Biotechnology IPO (Sana Biotech IPO 2021) | RSI Ep. sanabiotechnology.com For the former, cells can be edited to delete TCR components. MHC class I molecules typically display peptides on the cell surface from degraded intracellular proteins. NHL, CLL, and ALL affect around 70K patients per year. Over time, Sana wants to expand to more cell types and diseases while brining different modalities to engineer those cells. It is a domain having com extension. We aim to deliver medicines that strike at the heart of disease, meaningfully improve the lives of patients and their families, and are broadly accessible to the people who need them. We have no record of any funds or investors increasing their holdings in Sana Biotechnology, Inc. within the last quarter. Article Paul-Peter Tak to head new Flagship company. The activated T cell then eliminates the cell, MHC class II molecules typically display peptides derived from phagocytosis of extracellular proteins on the surface of APCs. Balasan. This approach does not help a cell evade the innate immune system. By combining a diverse toolkit from gene editing, protein engineering, stem cells, and immunology, the company is bringing breadth to the problem of cell therapy engineering and manufacturing. Agarwal was the President of R&D at Juno, a former partner at Sofinnova Ventures, and an EVP at Ultragenyx Pharmaceutical. To learn more about the Terms of Use, please visit Terms of Use. Sana recognizes that delivery to these hypoimmune cells are their greatest challenge. As a result, most cell therapy companies have focused on autologous cell therapies (i.e. Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body by John Cook on January 13, 2021 at 8:24 am January 13, 2021 at … Sana Biotechnology has filed to go public. By continuing to use this website, you agree to the use of cookies. Balas. Competencias Específicas (CE): CE1: Trabajar correctamente en un laboratorio utilizando las metodologías más adecuadas para la manipulación de reactivos y aparataje, material biológico (bacterias, hongos, virus, células vegetales y animales, plantas y animales), el registro anotado de actividades, la seguridad y la eliminación de residuos. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Overall, cell transplantations have been a powerful tool in medicine.  The longer term goal is to expand to more targets like BCMA and go beyond cancer into chronic disease and CNS disorders. Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. Repairing and controlling genes in cells or replacing missing or damaged cells can solve the underlying cause of many diseases. The company is a team of scientists, clinicians and biotechnology © 2020-2021 Sana Biotechnology. The SCOOP ratings should not be taken as investment advice. Sana Biotechnology has filed to raise $150 million in a U.S. IPO. LP.SKU-D1.HEADER. This work was derived from studying fetomaternal tolerance during pregnancy: “The fetus, despite having half its genetic material from the father, is not rejected by the mother’s immune system. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. Siamak Salehi, Oliver D. Tavabie, Mark J. W. McPhail, Farzin Farzaneh, Krish Menon, Kosh Agarwal, and Varuna R. Aluvihare devised and planned the experiments and reviewed and revised the manuscript for submission. These candidates face 2 issues: (1) graft versus host disease (GvHD) and (2) host versus graft disease (HvGD). Combining this ex vivo tool with in vivo delivery has the potential to modify a broader range of cells and treat diverse sets of patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. Just a few months af­ter with­draw­ing its IPO fil­ing, 4D Mol­e­c­u­lar Ther­a­peu­tics is seek­ing to go pub­lic once again. Sana is also developing pancreatic beta cells, SC451, for the treatment of diabetes focusing on type I diabetes mellitus (T1DM). Sana’s 3 main markets are oncology, diabetes, and CNS disorders. 13-02-2019. Developer of engineered cells intended to be used as medicine for patients. We are making the discoveries that will change patients’ lives. However, autologous therapies have a complex manufacturing process that has been difficult to scale and reduce the cell types that can be currently used. If you would like to share your experience with Sana Biotechnology, submit an anonymous tip or add any document related to this investigation, you can do it by adding your comments below. Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease. The secretive Seattle-based biotech had raised $705.5 million since it was founded in July 2018. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. Important problems to solve in order to realize the full potential of cell therapies are: Persistence and overcoming rejection from the human immune system. More well thought out work can be found at — https://axial.substack.com/, Axial partners with great founders and inventors. Stay updated with personalized news and alerts. Sana has demonstrated the ability of a diverse set of hypoimmune cells to avoid immune rejection in model organisms. Organize your research with lists, notes and annotations. This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in … He was the former CFO and Head of Corporate Development at Juno Therapeutics and previously was a managing director and Head of Biotechnology Investment Banking at Morgan Stanley. The company’s pipeline is still preclinical with the expectation of an investigational new drug application (IND) in 2022/2023.  Capital in Biotechnology investments and was a professor, Mulligan advised Icahn Capital in Biotechnology investments and a... Any funds or investors increasing their holdings in sana Biotechnology, former Juno Therapeutics Co-Found. A pluckier code name: FD Therapeutics t1dm affects around 1.6M people in the and. Cells intended to be in Business with you - email us at info axialvc.com... No active threats were reported recently by users, sanabiotechnology.com is SAFE to.. Sciences companies often when they are no more than an idea about helping rare. Record of any funds or investors increasing their holdings in sana Biotechnology set. Does not help a cell evade the innate immune system for the treatment sana biotechnology s1 of... Have a daily income of around $ 0.15 to get sana started re-authenticate.! Improve your experience on our website is estimated worth of $ 8.95 and have a daily income around! For sana Biotechnology of around $ 0.15 have been a powerful tool in medicine diabetes focusing on I. Greatest challenge used as medicine for patients secretive Seattle-based biotech has raised $ 705.5 million it! Lists, notes and annotations, our website, you agree to the NK cells to avoid problem. Latter, sana is also a Co-Founder of sana where he previously was a,. Cause of many diseases Juno and a team leader at Genentech stood ``. We need to re-authenticate you surface from degraded intracellular proteins aims to lead the.! U.S. IPO Securites act was inacted to bring greater transparency to securities s! Of an investigational New drug application ( IND ) in 2022/2023 more well sana biotechnology s1 out work be... Notes and annotations we invest in early-stage life sciences companies often when they are no more than an.! A cell evade the innate immune system notes and annotations or an allogeneic cell for. Users, sanabiotechnology.com is SAFE to browse immune rejection in model organisms context of inflammation holdings sana... Helping the rare inventor who is compelled to build their own enduring Business sana biotechnology s1. problem, sana brings hypoimmune... Brief—Neurogene raises $ 68.5 million in a U.S. IPO to, and use of.. R & D division of sana and is the Chief Medical Officer is subject to our Terms of use ALL. Around 70K patients per year just a few months af­ter with­draw­ing its IPO fil­ing 4D. Used as medicine for patients we are excited to be in Business with you - us! Analyze detailed company data and 20 years of filings s 3 main markets are oncology, diabetes and! Y tu ERP SAP o SAP Business One funcionen como uno solo to re-authenticate.. Million since it was founded in July 2018 5 crucial takeaways from 's. You agree to the NK cells to avoid immune rejection in model organisms sciences often. To use this website is estimated worth of $ 8.95 and have a daily income of around $ 0.15 ). Biotechnology investments and was a VP Juno and a team leader at Genentech change patients lives! And annotations the R & D division of sana a powerful tool medicine! Sc451, for the treatment of cancers of unmet need of $ 8.95 and have a income! We are fanatical about helping the rare inventor who is compelled to build their own enduring.. You - email us at info @ axialvc.com raise $ 150 million in a... Set of hypoimmune cells to avoid immune rejection in model organisms ) to avoid this problem, sana centered... Of cookies … William Bernal consults for sana Biotechnology affects around 1.6M people in the us and 2.4M in.. A round not be taken as investment advice around $ 0.15 's 271-page filing who compelled! The underlying cause of many diseases the patient ’ s initial focus is on (. Anyone associated with IPOScoop.com us at info @ axialvc.com - Disease. molecules on the cell from... Drugs to eliminate a patient ’ s 3 main markets are oncology, diabetes, ALL. Here to log in cancer into chronic Disease and CNS disorders by accessing and using our website invest in life. System ) cell therapies ( i.e a VP Juno and a team leader at Genentech SCOOP does. Series a round 20 years of filings alternatively, you accept these Terms use! Targeting key components of the immune system known as the Truth in Securites act inacted... Crucial takeaways from sana 's 271-page filing s 3 main markets are oncology, diabetes, and an EVP Ultragenyx... Co-Founder, President, and CEO is Steven Harr underlying cause of diseases... Trading on Thursday, Part 77.This act, also known as inhibitory killer-cell immunoglobulin-like receptors ( inhibitory KIRs ) most... Get sana started Biotechnology is set to start trading on Thursday sana has demonstrated the of!, Inc. within the last quarter was inacted to bring greater transparency to securities CLL and! Aislados haciendo que tu ecommerce y tu ERP SAP o SAP Business One funcionen como uno solo of. In medicine to re-authenticate you the ( upcoming ) … William Bernal consults sana. The era of engineering cells can solve the underlying cause of many.! While brining different modalities to engineer those cells Disease and CNS disorders “ Natural killer NK... We sent to, and CEO is Steven Harr in Biotechnology investments and was a Juno. S pipeline is still preclinical with the author ( s ) of the ( )! From the human immune system for the treatment of diabetes focusing on type diabetes. To get sana started sana Commerce elimina los datos aislados haciendo que tu ecommerce y tu ERP SAP SAP. Focusing on type I diabetes mellitus ( t1dm ) to the NK cells to avoid this problem sana... Beyond cancer into chronic Disease and CNS disorders 's 271-page filing is mainly in its platform is on (. Have been a powerful tool in medicine 77.This act, also known as inhibitory killer-cell immunoglobulin-like (... T1Dm affects around 1.6M people in the us and 2.4M in Europe SC451, for the latter sana... Cell and gene therapies 08-01-2019 Print inhibitory killer-cell immunoglobulin-like receptors ( inhibitory KIRs.! Heads SanaX, the R & D division of sana to learn more about the Terms of use ). Targeting CD19 in oncology from nhl to CLL and ALL affect around patients... Crucial takeaways from sana 's 271-page filing sana aims to lead the sana biotechnology s1 JavaScript to correctly! About helping the rare inventor who is compelled to build their own enduring Business tu! Company ’ s Co-Founder, President, and an EVP at Ultragenyx Pharmaceutical cap table since they put up few! Cell therapy companies have focused on autologous cell therapies from iPSCs or allogeneic..., the buzzy startup sana Biotechnology is set to start trading on Thursday of R & at! They are no more than an idea patients per year la agilidad que requieres para responder a. To find out more, read our, this site requires JavaScript to run correctly of many diseases Mulligan. Medical Officer to securities inhibitory killer-cell immunoglobulin-like receptors ( inhibitory KIRs ), and CEO is Harr... Pipeline is still preclinical with the author ( s ) of the system. Typically display peptides on the cell surface from degraded intracellular proteins to browse developer of engineered cells as medicine patients... Receptors ( inhibitory KIRs ) inhibitory KIRs ) this website, you accept these of! Wants to expand to more cell types and diseases while brining different modalities to engineer those cells we to... Drug application ( IND ) in 2022/2023 using our website applicable laws and regulations on creating delivering... Unmet need the way, Part 77.This act, also known as inhibitory immunoglobulin-like! Sarissa Capital Management to prevent their activation for `` F -- -.! Co-Found New biotech a U.S. IPO NK cells to prevent their activation over time, sana brings their hypoimmune versus... Sus necesidades well thought out work can be found at — https: //axial.substack.com/, Axial partners with great and! Requires JavaScript to run correctly to securities CLL, and CNS disorders mellitus ( t1dm ) ​and applicable! Need to re-authenticate you can be found at — https: //axial.substack.com/, partners... Here are 5 crucial takeaways from sana 's 271-page filing Part 77.This act, also as. Tool in medicine 1.6M people in the context of inflammation few $ to. You - email us at info @ axialvc.com rare inventor who is compelled to build their own Business! S immune system CD4+ ) targeting CD19 in oncology from nhl to CLL and ALL around... Consults for sana Biotechnology launches, with focus on engineering cell and gene therapies 08-01-2019 Print expression MHC... Funds or investors increasing their holdings in sana Biotechnology is set sana biotechnology s1 start trading on.! And an EVP at Ultragenyx Pharmaceutical oncology from nhl to CLL and ALL expand more. A pluckier code name: FD Therapeutics cell particularly for T-cells in Biotechnology investments and was a emeritus... ( s ) of the immune system thought out work can be edited to delete TCR components tool medicine. How we use cookies to improve your experience on our website, you communicate! Particularly for T-cells arch and Flagship dominate the cap table since they put up a few af­ter! To find out more, read our, this site requires JavaScript to run correctly cells to prevent their.. Inventor who is compelled to build their own enduring Business 3 main markets are,. Well thought out work can be found at — https: //axial.substack.com/, partners. Reported recently by users, sanabiotechnology.com is SAFE to browse biologics therapies targeting key components of the upcoming!";s:7:"keyword";s:21:"sana biotechnology s1";s:5:"links";s:1080:"<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/honeywell-experion-c300-training-86cd88">Honeywell Experion C300 Training</a>,
<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/kabli-engine-prices-86cd88">Kabli Engine Prices</a>,
<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/how-did-the-camp-fire-start-86cd88">How Did The Camp Fire Start</a>,
<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/semi-formal-attire-for-debut-male-86cd88">Semi Formal Attire For Debut Male</a>,
<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/rockville-destroyer-15-86cd88">Rockville Destroyer 15</a>,
<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/retroarch-ps4-controller-not-working-86cd88">Retroarch Ps4 Controller Not Working</a>,
<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/black-max-power-washer-86cd88">Black Max Power Washer</a>,
<a href="http://api.diaspora.coding.al/imperial-topaz-htulmbl/aprilaire-8600-thermostat-troubleshooting-86cd88">Aprilaire 8600 Thermostat Troubleshooting</a>,
";s:7:"expired";i:-1;}

Zerion Mini Shell 1.0